| Pulmonary arterial hypertension
Orenitram vs WINREVAIR
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Orenitram vs Winrevair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWinrevair has a higher rate of injection site reactions vs Orenitram based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Winrevair but not Orenitram, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orenitram
Winrevair
At A Glance
Oral
Two to three times daily
Prostacyclin mimetic
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Starting dose 0.125 mg TID or 0.25 mg BID with food; titrate by 0.125 mg TID or 0.25-0.5 mg BID no more frequently than every 3-4 days; maximum daily dose 120 mg.
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Contraindications
- Severe hepatic impairment (Child Pugh Class C)
—
Adverse Reactions
Most common (>10%) Headache, diarrhea, nausea, vomiting, jaw pain, flushing
Postmarketing Dizziness, dyspepsia, vomiting, myalgia, arthralgia
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Pharmacology
Prostacyclin mimetic; treprostinil causes direct vasodilation of pulmonary and systemic arterial vascular beds, inhibits platelet aggregation, and inhibits smooth muscle cell proliferation.
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orenitram
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Winrevair
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Orenitram
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (5/8)
Winrevair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
Humana
Orenitram
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Winrevair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Merck Access Co-pay Assistance: WinrevairCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrenitramView full Orenitram profile
WinrevairView full Winrevair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.